Utama › Kanser Paru-paru › Massachusetts › Worcester
Kajian klinikal Kanser Paru-paru di Worcester, MA
11 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Worcester (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- UMass Memorial Medical Center - University Campus, Worcester
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Mengambil pesertaFasa 3
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford · 17 mi jauh
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Mengambil pesertaFasa 3
- UMass Memorial Medical Center - University Campus, Worcester
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- UMass Memorial Medical Center - University Campus, Worcester
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Mengambil pesertaFasa 3
- Reliant Medical Group Inc, Worcester
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- University of Massachusetts Memorial Medical Center, Worcester
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- UMass Memorial Medical Center - University Campus, Worcester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- UMass Memorial Medical Center - University Campus, Worcester
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- UMass Memorial Medical Center - University Campus, Worcester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- UMass Memorial Medical Center - University Campus, Worcester
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Worcester
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Worcester
- Kanser Paru-paru Bukan Sel Kecil14 kajian
- Kanser (semua jenis)7 kajian
- Kanser Payudara6 kajian
- Skizofrenia5 kajian
- Kanser Metastatik5 kajian
- Kanser Prostat5 kajian
- Kanser Ovari5 kajian
- Gangguan Depresi Major5 kajian
- Depresi5 kajian
- Leukemia Mieloid Akut5 kajian
- Karsinoma Urotelial (Sel Transisi)4 kajian
- Kanser Pundi Kencing4 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.